These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24092335)

  • 1. Pulmonary hypertension: pathophysiology and signaling pathways.
    Maron BA; Loscalzo J
    Handb Exp Pharmacol; 2013; 218():31-58. PubMed ID: 24092335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of dietary iron restriction on the development of monocrotaline-induced pulmonary vascular remodeling and right ventricular failure in rats.
    Naito Y; Hosokawa M; Hao H; Sawada H; Hirotani S; Iwasaku T; Okuhara Y; Eguchi A; Hirota S; Ohyanagi M; Tsujino T; Masuyama T
    Biochem Biophys Res Commun; 2013 Jun; 436(2):145-51. PubMed ID: 23707944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cellular signalling pathways and pathophysiology of pulmonary arterial hypertension].
    Dao P; Montani D; Duong-Quy S; Dinh-Xuan AT
    Rev Mal Respir; 2006 Feb; 23(1 Suppl):3S75-83. PubMed ID: 16604016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel concepts in the pathobiology of pulmonary arterial hypertension].
    Rosenkranz S
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S167-9. PubMed ID: 18814087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.
    Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM
    Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.
    Leopold JA; Maron BA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension.
    Berghausen E; ten Freyhaus H; Rosenkranz S
    Handb Exp Pharmacol; 2013; 218():381-408. PubMed ID: 24092349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pulmonary hypertension: from molecular pathophysiology to haemodynamic abnormalities].
    Duong-Quy S; Rivière S; Bei Y; Duong-Ngo C; Le-Dong NN; Hua-Huy T; Dinh-Xuan AT
    Rev Mal Respir; 2012 Oct; 29(8):956-70. PubMed ID: 23101638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactive oxygen species as therapeutic targets in pulmonary hypertension.
    Freund-Michel V; Guibert C; Dubois M; Courtois A; Marthan R; Savineau JP; Muller B
    Ther Adv Respir Dis; 2013 Jun; 7(3):175-200. PubMed ID: 23328248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exercise physiology and pulmonary arterial hypertension.
    Waxman AB
    Prog Cardiovasc Dis; 2012; 55(2):172-9. PubMed ID: 23009913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases.
    Dupuis J; Guazzi M
    Can J Cardiol; 2015 Apr; 31(4):416-29. PubMed ID: 25840093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Right ventricular electrical remodeling and arrhythmogenic substrate in rat pulmonary hypertension.
    Tanaka Y; Takase B; Yao T; Ishihara M
    Am J Respir Cell Mol Biol; 2013 Sep; 49(3):426-36. PubMed ID: 23600532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models related to congenital heart disease and clinical research in pulmonary hypertension.
    Loukanov T; Geiger R; Agrawal R
    Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension.
    Pullamsetti SS; Doebele C; Fischer A; Savai R; Kojonazarov B; Dahal BK; Ghofrani HA; Weissmann N; Grimminger F; Bonauer A; Seeger W; Zeiher AM; Dimmeler S; Schermuly RT
    Am J Respir Crit Care Med; 2012 Feb; 185(4):409-19. PubMed ID: 22161164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic regulation of pulmonary arterial hypertension.
    Xu XF; Cheng F; Du LZ
    Hypertens Res; 2011 Sep; 34(9):981-6. PubMed ID: 21677658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension.
    Kanki-Horimoto S; Horimoto H; Mieno S; Kishida K; Watanabe F; Furuya E; Katsumata T
    Circulation; 2006 Jul; 114(1 Suppl):I181-5. PubMed ID: 16820570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension.
    Klinger JR; Abman SH; Gladwin MT
    Am J Respir Crit Care Med; 2013 Sep; 188(6):639-46. PubMed ID: 23822809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
    Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
    Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase-5 inhibitors.
    Cockrill BA; Waxman AB
    Handb Exp Pharmacol; 2013; 218():229-55. PubMed ID: 24092343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension.
    Dumas de la Roque E; Savineau JP; Bonnet S
    Pharmacol Ther; 2010 May; 126(2):186-99. PubMed ID: 20206649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.